Abiopharma

🔍 Agarwal Amit (Director)

Company: Datadog, Inc. (DDOG)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Class A Common Stock (Direct)
  Date: 2026-03-16 | Code: C | equity_swap_involved: 0 | shares_owned_after: 21,640.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 15,796 shares of Class A Common Stock at $126.338 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,844.00 | transaction_form_type: 4 | Footnotes: F3, F4, F2
• Sold 4,000 shares of Class A Common Stock at $128.1991 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,844.00 | transaction_form_type: 4 | Footnotes: F3, F5, F2
• Sold 204 shares of Class A Common Stock at $128.6365 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,640.00 | transaction_form_type: 4 | Footnotes: F3, F6, F2
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-03-16 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 6,541.00 | Footnotes: F7
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-03-16 | Code: H | shares_owned_after: 27,999.00
• Sold 20,000 shares of Class B Common Stock (Derivative)
  Date: 2026-03-16 | Code: C | equity_swap_involved: 0 | shares_owned_after: 550,059.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2
• Holds 603,464 shares of Class B Common Stock (Derivative)
  Date: 2026-03-16 | Code: H | shares_owned_after: 603,464.00 | Footnotes: F1, F1, F1, F7
• Holds 53,063 shares of Class B Common Stock (Derivative)
  Date: 2026-03-16 | Code: H | shares_owned_after: 53,063.00 | Footnotes: F1, F1, F1, F8

Footnotes:

• F1: Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon the earliest of: (i) any transfer, whether or not for value, except for certain "Permitted Transfers" as defined in the Issuer's amended and restated certificate of incorporation, (ii) the death of the Reporting Person in the case of shares held directly or in a trustee capacity, and (iii) the tenth anniversary of the Issuer's initial public offering of its Class A Common Stock.
• F2: Shares are held directly by Agarwal 2018 Family Trust, of which the Reporting Person's spouse is Trustee.
• F3: Shares sold pursuant to a 10b5-1 plan dated December 8, 2025.
• F4: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $125.86 to $126.84. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F5: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $127.58 to $128.57. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F6: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $128.61 to $128.65. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F7: Shares are held directly by Agarwal 2019 Family Trust, of which the Reporting Person's spouse is Trustee.
• F8: Shares are held by Reporting Person's spouse.